Stocks in play: Medicenna Therapeutics Corp.
Today reported financial results and corporate highlights for the fiscal quarter ended June 30, 2025. For the three months ended June 30, 2025, the Company reported total operating costs of $5.5 million compared to total operating costs of $4.0 million for the three months ended June 30, 2024. Net loss for the quarter was $4.9 million or $0.06 per share compared to a net loss of $3.6 million or $0.05 per share for the three months ended June 30, 2024. Medicenna Therapeutics Corp. shares T.MDNA are trading unchanged at $0.84.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.